Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDA 002

Next Previous
Drug Profile

PDA 002

Alternative Names: PDA-002; PDAC cells; Placental-derived adherent cells intramuscular

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Celularity
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer
  • Phase I/II Facioscapulohumeral muscular dystrophy
  • No development reported Peripheral arterial disorders
  • Discontinued Diabetic neuropathies

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for phase-I development in Peripheral-arterial-disorders in USA (IM)
  • 04 Nov 2025 Phase-II clinical trials in Diabetic foot ulcer (IM) (prior to November 2025) (Celularity pipeline, November 2025)
  • 04 Nov 2025 Celularity announces intention to submit the regulatory application to the US FDA for Diabetic foot ulcers and Peripheral arterial disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top